Creative Biolabs Facilitates Innovative Anti-SARS-CoV-2 Drug Discovery

(Isstories Editorial):- New York City, New York Aug 6, 2023 (Issuewire.com) – Creative Biolabs, a well-established contract research organization (CRO) specializing in antiviral research, has dedicated years to the development of anti-SARS-CoV-2 drugs, amassing extensive expertise in this critical area.

With a strong commitment to combating the COVID-19 pandemic, Creative Biolabs offers an all-in-one platform for antiviral drug development, equipped with advanced evaluation tools to identify promising SARS-CoV-2 drug candidates effectively.

Laboratory researchers at Creative Biolabs explain, “Over the years of grappling with the pandemic, we have continuously accumulated and updated our knowledge and experience in antiviral drug development, providing a comprehensive platform with solutions such as high-throughput screening to explore candidates, neutralizing antibody development, and SARS-CoV-2 complement therapy.”

More on Isstories:

Neutralizing antibodies have long been recognized for their ability to neutralize most viral invaders. In the face of the formidable COVID-19 outbreak, Creative Biolabs naturally leverages the potential of neutralizing antibodies for research. The researchers at Creative Biolabs discovered that CR3022, an antibody, binds to a site on the SARS-CoV-2 receptor-binding domain that does not overlap with ACE2, demonstrating a unique and highly effective binding property, capable of specific binding to the SARS-CoV-2 virus. This extraordinary antibody precisely targets specific viral antigens to neutralize the virus and prevent it from entering host cells.

Thus, at Creative Biolabs, CR3022 SARS-CoV-2 is considered a primary target for antibody development. Other solutions offered by Creative Biolabs include:

* CD4 as a Target for SARS-CoV-2 Antibody Development

* Glycoprotein as a Target for SARS-CoV-2 Antibody Development

* Human monoclonal antibodies extracted from the blood serum of COVID-19-recovered patients

In addition to the neutralizing antibody solution, Creative Biolabs has achieved significant breakthroughs in specifically targeting the SARS-CoV-2 virus using complement therapy. Researchers have designed a series of novel complementary therapeutic approaches based on complement proteins in the immune system, showing promising prospects in reducing the severity of COVID-19 and lowering viral loads in infected individuals. The complement therapy for SARS-CoV-2 offered by Creative Biolabs targets the following three types of complement proteins:

* Targeting complement activating factors, C1, MASP

* Targeting complement regulators, C1-INH

* Targeting complement receptors and ligands, C5a, C5aR1, C3a

Understanding the urgency of effectively evaluating SARS-CoV-2 candidates, Creative Biolabs has also designed an innovative evaluation platform for SARS-CoV-2 drugs. This meticulously designed platform helps clients rapidly and accurately screen a large number of candidate molecules, streamlining the drug development process and prioritizing the most promising leads for further development.

The researchers state, “With this advanced one-stop platform, Creative Biolabs is confident in accompanying scientists worldwide to continue facing the challenges posed by SARS-CoV-2 and making a positive impact.”

For more information about Creative Biolabs’ pioneering anti-SARS-CoV-2 drug development services and products, please visit https://sars-cov-2.creative-biolabs.com.

About

Creative Biolabs is a leading biotechnology company specializing in innovative research solutions. With a focus on infectious diseases, including COVID-19, Creative Biolabs is committed to advancing scientific knowledge and contributing to global health.

 

Media Contact
Creative Biolabs

RELATED ARTICLESMORE FROM AUTHOR